REVIEW

Aptamer–nanoparticle complexes as powerful diagnostic and therapeutic tools

Hunho Jo and Changill Ban

Correct diagnosis and successful therapy are extremely important to enjoy a healthy life when suffering from a disease. To achieve these aims, various cutting-edge technologies have been designed and fabricated to diagnose and treat specific diseases. Among these technologies, aptamer–nanomaterial hybrids have received considerable attention from scientists and doctors because they have numerous advantages over other methods, such as good biocompatibility, low immunogenicity and controllable selectivity. In particular, aptamers, oligonucleic acids or peptides that bind to a specific target molecule, are regarded as outstanding biomolecules. In this review, several screening techniques for aptamers, also called systematic evolution of ligands by exponential enrichment (SELEX) methods, are introduced, and diagnostic and therapeutic aptamer applications are also presented. Furthermore, we describe diverse aptamer–nanomaterial conjugate designs and their applications for diagnosis and therapy.

Experimental & Molecular Medicine (2016) **48**, e230; doi:10.1038/emm.2016.44; published online 6 May 2016

INTRODUCTION

For several decades, nanotechnology has made remarkable advancements in various fields, such as electricity, communication, material science, manufacturing, medical treatment and life sciences. In particular, the convergence of biomolecules and nanomaterials has led to a breakthrough in the diagnosis and therapy of specific diseases, including cancers. Biocompatible molecules, like DNA, RNA and peptides, enable specific targeting and imaging. Moreover, the unique spectroscopic and thermotherapeutic properties of nanomaterials provide superior advantages for sensing, imaging and therapeutic applications. As shown in Figure 1, biomolecule–nanomaterial hybrids are readily applicable to many areas.

In particular, accurate diagnosis and effective therapy have been regarded as key factors in the medical field. The development of next-generation materials for successful diagnosis and therapy has been an important research focus. Among many substances, aptamers are recognized as one of several remarkable agents because of their valuable properties.^{1,2} Aptamers are oligonucleic acids or peptides that have high sensitivity and robust selectivity toward several types of target molecules, including proteins, nucleotides, peptides, antibiotics, small molecules and cells.³ Small nucleic acid aptamers exhibit good stability in severe conditions, and peptide

aptamers have suitable structures that interact with target molecules. All types of aptamers contain a variable loop and stem region that bind to a specific pocket of target molecules. Aptamers have diverse advantages over antibodies, including small size, easy modification and high stability in harsh physical and chemical environments, as well as rapid and economical production, no batch-to-batch variation, low immunogenicity and high flexibility.⁴ Therefore, aptamers are regarded as excellent substitutes for antibodies during targeting and imaging in medical sciences, and are used in an assortment of fields.

The development of numerous nanomaterials has accelerated advancements in diagnosis and therapy.⁵ A variety of nanomaterials, such as hydrogels, metallic nanoparticles, silica nanoparticles and carbon materials, have ideal characteristics, including controllable physical and chemical properties, a large surface area, robust biocompatibility and outstanding stability.^{6,7} Even though nanomaterials themselves can be used as diagnostic and therapeutic agents, they lack selective targeting ability. Therefore, a number of aptamer–nanomaterial complexes have been designed and applied to multiple areas.^{8–10}

In this review, we focus on an overview of recent improvements for aptamer and aptamer–nanomaterial conjugates, as well as their applications for the diagnosis and treatment of several diseases.

Department of Chemistry, Pohang University of Science and Technology, Pohang, Gyeongbuk, South Korea

Correspondence: Dr H Jo or Professor C Ban, Department of Chemistry, Pohang University of Science and Technology, 77, Cheongam-Ro, Nam-Gu, Pohang,

Gyeongbuk 790-784, South Korea.

E-mail: jhhsst@gmail.com or cibn@postech.ac.kr

Received 12 January 2016; accepted 5 February 2016

Figure 1 Applications of biomolecule–nanomaterial complexes.

IN VITRO SCREENING FOR APTAMERS

Target-specific aptamers are selected *in vitro* using a process, called systematic evolution of ligands by exponential enrichment (SELEX).^{11,12} As represented in Figure 2a, SELEX is a repetition of four main steps: target incubation with aptamer libraries encoding random sequences, usually 30–50 mers, and the primer-binding site; elution of bound libraries; amplification with polymerase chain reaction; and single-stranded oligonucleotide separation. This procedure is generally repeated 10–15 times, and then the selected aptamer candidates are analyzed using cloning techniques.

To develop aptamers to recognize proteins or small molecules, five types of SELEX have been generally applied. The first method, nitrocellulose membrane filtration-based SELEX, has been used since 1990, when it was designed by Tuerk and Gold.¹² The role of nitrocellulose membrane is to only filter libraries that can bind to the protein based on specific protein-binding affinity. However, this method is limited to only proteins because the nitrocellulose membrane is capable of binding proteins. The second method is affinity chromatography-based SELEX, which uses the specific interaction between immobilized beads and their target molecules. When the library is loaded onto the target-immobilized affinity column, the non-binding fraction is washed via flow-through, and a binding library is obtained.¹³ However, this method is confined because it requires a functional group or affinity tag on the target molecule. In addition, functionalized magnetic bead-based SELEX has frequently been applied to discover new aptamer candidates. Target molecules are immobilized on a magnetic bead using a covalent bond, a specific interaction or an electrostatic interaction between a substrate on the beads and a specific tag on the target molecule.¹⁴ Easy and rapid separation of the library bound to the target using an external magnet makes this SELEX method valuable. In addition, capillary electrophoresis-based SELEX has many advantages, such as fast separation, high resolution, large capacity and a small amount of samples.¹⁵ Under an electric field, each molecule is separated based on its charge, hydrodynamic radius

and frictional force. SELEX can be accomplished within a few cycles using this method. Finally, SELEX is performed with a microfluidic chip-based technique, which offers good selection efficiency on a small scale and rapid separation via automatic continuous-flow.¹⁶ The development of microfluidic chip technology has the potential to enable fast and convenient SELEX.

On the other hand, aptamers for comparatively large targets, such as cancer cells, have been identified via another method as described in Figure 2b. Because almost all aptamers recognize the surface biomarkers on cancers, this method is termed ‘cell-based SELEX’.¹⁷ Miscellaneous hindrances on the cell surface, such as many non-target proteins, glycosides and various receptors, make negative selection essential during each cycle. Although this method requires multiple cycles, it is significant enough to generate aptamers identifying target cells that do not overexpress biomarkers.

In recent years, the convergence of new technologies and SELEX has allowed effective and economic aptamer screening. Computational approaches have been introduced to SELEX for the prediction and optimization of aptamer structures, binding affinity and thermodynamic characteristics.¹⁸ Several programs, such as Resetta,¹⁹ FR3D²⁰ and MPBind,²¹ have been developed and utilized for 3D structure predictions of aptamers.²² In addition, a high-throughput sequencing technique has been used for its high efficiency and extensive applicability. High-throughput sequencing offers the complete sequence analysis of aptamer candidates, exact quantification, the comparison of binding motifs among each sequence and the characterization of binding affinities.^{23,24} Such substantial advances in SELEX methods have generated noteworthy outgrowth in the design and identification of new aptamers, and further modifications of SELEX have been successful in the innovations for screening aptamers.

DIAGNOSTIC APPLICATIONS OF APTAMERS

Highly sensitive and selective aptamers have boundless potential applications as diagnostic molecules. Diagnostic methods are commonly categorized according to three

Figure 2 The SELEX procedure. (a) A schematic illustration for general SELEX. It consists of four steps: incubation of target molecules with libraries, elution of bound libraries, amplification of the libraries and separation of the libraries for the next round. (b) A schematic illustration of cell-based SELEX. Negative selection is required for each round.

approaches based on detection principles. In the first approach, aptamers are often used to fabricate electrochemical biosensors, which can provide an accurate, rapid and sensitive diagnosis. Figure 3a depicts an example of electrochemical impedance spectroscopy using aptamers.²⁵ These electrochemical detection methods, including cyclic voltammetry and differential pulse voltammetry, have many advantages, such as reproducibility, a rapid response, no probe labeling, high sensitivity and selectivity, and no need for high-cost instrumentation.²⁶ In addition, aptamers are valuable probes in colorimetry. Detection in colorimetry uses color changes in some of the particles, and a gold nanoparticle (AuNP) is one of the best indicators for this method. Its unique characteristics, such as a positive charge, color change according to interparticle distance and absorption of the thiol group, enable rapid and convenient detection. As shown in Figure 3b, the target protein can simply be detected by the AuNP color change.²⁷ The presence of the target protein is confirmed by the competitive binding of the polymers. Fluorescence-based diagnosis is also used in

aptamer-based detection, which is a powerful diagnostic and bioanalytical platform. The introduction of aptamers to fluorometry has created a synergistic effect. Recently, Roncancio *et al.*²⁸ reported a rapid and specific aptamer-based platform for one-step cocaine detection using minimal reagent requirements, and verified that this sensor detects cocaine with a detection limit of 200 nM, which is 50-fold lower than the existing limit (Figure 3c).

Moreover, it is well-known that aptamers have been commonly utilized for other diagnostic research, such as single-wall nanotube-based detection, surface acoustic waves, surface plasmon resonance, micro cantilever sensing and quartz crystal microbalance.^{29–32} Aptamers are novel and invaluable next-generation targeting probes that are readily applicable to target-specific diagnosis.

THERAPEUTIC APPLICATIONS OF APTAMERS

Some aptamers have shown high binding affinity for target molecules and an antagonistic effect on specific functions of the

Figure 3 Various applications of aptamers for detection. **(a)** Electrochemical impedance spectroscopic detection for MUC1. This image was adapted from Chen *et al.*²⁵ **(b)** Colorimetric detection. This image was adapted from Jeon *et al.*²⁷ **(c)** Fluorescent detection. This image was adapted from Roncancio *et al.*²⁸ Apt, aptamer; ATMND, 2-amino-5,6,7-trimethyl-1,8-naphthyridine; PDDA, poly (diallyldimethylammonium chloride); pLDH, *Plasmodium* lactate dehydrogenase; PoPD, poly(α -phenylenediamine); TEOS, tetraethyl orthosilicate; Thi, thionine.

targets, allowing their use as probes and drugs. Dating from the discovery of Mucugen, a vascular endothelial growth factor-specific aptamer, in 2004 and its approval by the US Food and Drug Administration as a new drug for treating age-related macular degeneration, diverse aptamers have been recognized as effective drugs for specific diseases. For example, ARC1779 (Archemix, Cambridge, MA, USA) targets activated von Willibrand Factor and was designed as a drug for purpura (Figure 4a). NOX-A12 (NOXXON Pharma, Berlin, Germany), which targets CXCL12, was developed to treat multiple myeloma and non-Hodgkin's lymphoma (Figure 4b).^{33,34} Aptamers themselves can be valuable, useful and effective medicines.

In addition, aptamers have been used as good drug carriers. The intercalating properties of nucleic acid aptamers mean that they are selective and sensitive delivery vehicles. On the basis of the fact that doxorubicin, an anti-cancer drug, can easily intercalate into an A10 aptamer that recognizes prostate-specific membrane antigen (PSMA), which is overexpressed prostate cancer, a remarkable drug carrier was designed.³⁵ The dual-aptamer complex is specific for both PSMA (+) and (−) prostate cancer cells and delivers doxorubicin to the target cells incredibly effectively and selectively. Furthermore, aptamers can be used only as targeting molecules. For instance, the combination of an aptamer and siRNA generates marvelous therapeutic effects.³⁶ Direct conjugation between the targeting probe and siRNA provides a simple and convenient preparation method for the drug. Countless studies have been vigorously performed examining aptamers.

APTAMER-NANOMATERIAL COMPLEXES IN DIAGNOSIS

Quantum dots (QDs), semiconductor nanocrystals, have been gradually used in biological and medical diagnoses owing to their inimitable features, such as low photobleaching, high resistance to harsh chemical degradation, high-quantum yield and broad absorption with narrow photoluminescence spectra.³⁷ In particular, QDs have been regarded as excellent Förster resonance energy transfer (FRET) donors. The basic principle in FRET-based sensors is a target-dependent change in fluorescence signal caused by the distance between a donor and an acceptor. Representative FRET-based sensors using QDs are highlighted in Figure 5a.³⁸ Good FRET properties make aptamer-modified QDs particularly useful as probes in diagnosis. In 2009, Zhang *et al.*³⁹ designed a cocaine-specific detection platform. The Cyanine5-modified cocaine aptamer is hybridized to its complementary DNA, which is immobilized on the surface of the QD, resulting in huge FRET fluorescence. The selective binding between cocaine and the cocaine aptamer triggers a decrease in Cyanine5 fluorescence. Therefore, QD-based detection offers highly sensitive and selective detection of target molecules.

AuNPs are one of the best sensing nanomaterials and stable metallic nanoparticles. They retain many superior advantages over other nanomaterials for various reasons, including their tunable size and shape, easy and economic preparation, size-dependent electronic and optical properties, good biocompatibility, high intracellular stability, quenching ability and strong interaction with thiol functional groups.⁴⁰ Therefore, studies investigating AuNP-based detection have been

Figure 4 Examples of antagonistic aptamers. (a) The ARC1779 aptamer.³³ ARC1779 is conjugated to a 20-kDa PEG at the 5'-terminus (underline indicates 2'-O-methoxy nucleotides). (b) The NOX-A12 aptamer.³⁴ it, inverted deoxythymidine; ps, phosphorothioate linkage.

Figure 5 Diagnostic applications of biomolecule-nanomaterial complexes. (a) Three types of FRET-based detection using QDs: detection using quencher-modified oligonucleotides, detection using fluorophore-modified oligonucleotides and detection using intercalating dyes. This image was adapted from Zhou.³⁸ (b) Detection platform for breast cancer using dual-aptamer-modified SiNPs. HER2(+) or MUC1(+) breast cancer cells are selectively separated using dual-aptamer-modified magnetic beads, and SiNP conjugates are incubated with the magnetic beads-cell complexes. Breast cancer cells are quantified based on fluorescence from dyes inside the SiNPs. This image was adapted from Jo *et al.*⁴⁵ Ex, excitation.

performed for a long time. Aptamers can provide targeting abilities to AuNPs, therefore, aptamer-modified AuNPs are extremely useful diagnostic complexes. Target-specific AuNP probes have been designed to have various characteristics in countless assays, including colorimetry, fluorometry, electrochemical detection, surface plasmon resonance, surface-enhanced Raman spectroscopy and quartz crystal microbalance. For instance, Medley *et al.*⁴¹ designed a simple

and rapid detection method for cancer cells using aptamer-modified AuNPs. Aptamer-modified AuNPs selectively bind to target cells, and the interparticle distance decreases between the AuNPs, which generates discernible color changes from red to violet, leading to the straightforward detection of cells. The superquenching capacity of AuNPs is also a unique feature. Song *et al.*⁴² developed an ampicillin-specific AuNP sensor. When 5'-fluorescein amidite-modified aptamers are adsorbed

Figure 6 Therapeutic applications of biomolecule–nanomaterial complexes. (a) PTT using dual-aptamer-modified AuNSs. Aptamer–AuNS agents selectively induce apoptosis by generating considerable heat (A10 aptamer for PSMA (+) cancer cells and DUP1 aptamer for PSMA (–) cells). This image was adapted from Jo *et al.*⁵¹ (b) Aptamer-modified drug-encapsulated liposome. This image was adapted from Kang *et al.*⁵⁴ PEG, polyethylene glycol; TMR, tetramethylrhodamine.

to the AuNP surface via columbic interaction, quenching of the fluorophore occurs. Competitive binding of the ampicillin aptamer to AuNPs and ampicillin enables the restoration of fluorescence from fluorescein amidite, resulting in the sensitive quantification of ampicillin levels. In addition to these, aptamer–AuNPs have been applied to diagnose several specific diseases and to identify several molecules as well.

It has been known that silica nanoparticles (SiNPs) possess facile fabrication, easy surface modification, good biocompatibility, economic synthesis, hydrophilic properties and sterically hinder nucleases, which cleave DNA on the surface of the particle.⁴³ In particular, dye-doped SiNPs have received considerable attention as excellent probes due to their high-fluorescence intensity, robust signal and robust resistance to photobleaching, which hinders the fluorescence signals from almost all organic dyes. Coulombic interactions between positively charged dye molecules and the negatively charged silica matrix reinforces the resistance of SiNPs against photobleaching. Aptamer-modified, dye-doped SiNPs are actively utilized in many diagnosis studies. Mucin 1 (MUC1) aptamer-immobilized, dye-entrapped SiNPs were synthesized by Cai *et al.*⁴⁴ and exhibited an incredibly steady fluorescence signal and high selectivity toward MUC1 (+) cell lines only. Recently, the diagnosis of breast cancer using dual-aptamer-functionalized SiNPs was successfully performed.⁴⁵ As shown in Figure 5b, using dye-doped SiNPs modified with a MUC1 aptamer and a human epidermal growth factor receptor 2 aptamer, various types of breast cancer cell lines overexpressing MUC1 or human epidermal growth factor receptor 2 were

quantified. Therefore, specific aptamer-modified SiNPs can function as beneficial diagnostic tools for certain targets.

In contrast with other nanoparticles, magnetic nanoparticles (MNPs) have a peculiar trait that improves the magnetic resonance of adjacent water.⁴⁶ In particular, the aggregation of MNPs can cause the coupling of spin magnetic moments and produces strong local magnetic fields, resulting in accelerated dephasing of water protons.⁴⁷ A change in proton relaxation times, produced by a decrease of transverse or spin–spin relaxation times (T_2), enables the detection of MNP clusters via nuclear magnetic resonance, magnetic resonance imaging or relaxometry. On the basis of this principle, a simple detection method for lysozymes was developed.⁴⁷ The presence of lysozymes provokes the destruction of aggregated MNPs, leading to an increase in T_2 . This sensing platform provides a relatively high detection limit of 0.5 nM.

APTAMER–NANOMATERIAL COMPLEXES IN THERAPY

As previously described, QDs have notable features as probe molecules. For the application of QDs to therapy, photodynamic therapy (PDT) using QDs and photosensitizers has been conducted.¹⁰ However, comparatively low apoptotic effects and lack of targeting ability have been cited as some drawbacks of PDT. Therefore, the direct delivery of drugs via aptamer-modified QDs is favored rather than PDT. The intercalating properties of several drugs into DNA or RNA aptamers allow selective and effectual therapy. The combination of drug-intercalated aptamers and QDs facilitates simultaneous imaging and therapy. For example, Bagalkot *et al.*³⁷ designed a theranostic complex using aptamer-modified QDs.

Doxorubicin-intercalated aptamer-QD complexes exhibited no fluorescence signal because of FRET. However, after internalization of the complex into target cells via a specific interaction between the aptamer and target surface proteins, intercalated doxorubicin was released inside the cell by lysosomes, resulting in strong fluorescence from QDs and apoptosis by doxorubicin. QD complexes can be used for the dual functions of detection probes and delivering drugs.

Photothermal therapy (PTT) has been used in cancer therapy because it is non-invasive compared with radiation therapy, chemotherapy and surgery. Using near-infrared light, photothermal agents can effectively kill target cells and minimize unwanted injury to surrounding non-target cells.⁴⁸ Of the various photothermal probes, AuNPs are one of the most attractive particles because they enhance the damage induced by radiation and produce high heat upon near-infrared radiation.⁴⁹ Particularly, aptamer-immobilized AuNPs are noteworthy in targeted therapy. For instance, Wang *et al.*⁵⁰ designed a smart complex that can selectively and sensitively kill target cells via PTT, as well as via PDT. As aptamer-photosensitizer-gold nanorods (rod-shaped AuNPs) can target-specific cells using aptamers, and can also destroy cells using PTT and PDT, ultra-efficient therapy is achievable. Furthermore, multiple aptamer-modified gold nanostars (AuNSs) were also developed, as represented in Figure 6a.⁵¹ Newly synthesized AuNSs complexes showed high selectivity toward PSMA(+) and PSMA(-) cells, and extremely high efficiency for PTT using an 808-nm laser under an irradiance of 0.3 W cm^{-2} . In addition, AuNPs can be used as drug-delivery vehicle, as mentioned previously. Luo *et al.*⁵² fabricated a drug-delivery conjugate based on AuNPs. A drug intercalated in the aptamers can be released by irradiation, leading to selective and effective therapy.

It is widely known that liposomes encapsulate not only hydrophilic therapeutic drugs inside the aqueous center, but also hydrophobic therapeutic drugs within the bilayer membrane.⁵³ Studies on liposome therapy have been performed for a long time, and a few liposome-based drugs have already been approved for clinical use. The immobilization of aptamers onto the liposome surface can assign targeting capabilities to the liposome. In 2010, Kang *et al.*⁵⁴ fabricated sgc8 aptamer-modified, liposome-targeting CEM-CCRF cells. Aptamers were immobilized on a dextran-encapsulated PEG-liposome, and then applied to CEM-CCRF cells, resulting in highly effective and selective apoptosis of target cells (Figure 6b).

In addition, micelles have also been frequently utilized in therapeutic applications and are a cluster of surfactants such as soap, phospholipids and fatty acids. In an aqueous solution, the hydrophobic tails aggregate in the center of a micelle, and the polar heads are oriented toward the outside. Therefore, targeting molecule-modified micelles can selectively deliver hydrophobic anti-cancer drugs analogous to liposome-based carriers. Mu *et al.*⁵⁵ designed the FB4 APP (aptamer-modified PEG-poly(lactic acid) micelles) that targets the TfR on endothelial cells in the brain. For therapy, flurbiprofen, a potential

Alzheimer's disease drug, was encapsulated inside APP molecules, and the drug complexes were applied to target cells. The micelle-based complex showed increased binding efficiency in the target brain cells.

Of the several types of magnetic particles, superparamagnetic iron oxide nanoparticles (SPIONs) possess distinct characteristics, including good dispersibility, biocompatibility and anti-biofouling properties that inhibit the adsorption of plasma proteins or cells onto their surface.⁵⁶ They have been used as magnetic resonance contrast agents or magnetic field-guided drug-delivery vehicles. For the application of these molecules to therapy, drug-intercalated aptamers are immobilized on the surface of SPION in a similar manner. Thermally cross-linked SPION was modified with PSMA (+) and (-) aptamers and doxorubicin.³⁵ According to the results, this complex can selectively and effectively release the drug to prostate cancer cells.

CONCLUDING REMARKS

In this review, we have discussed a range of applications for aptamers and aptamer-nanomaterial complexes in diagnosis and therapy. The merging of aptamers and nanomaterials can provide a highly sensitive biosensing system, target-specific imaging and efficient therapy. Outstanding improvements in nanotechnology and biotechnology have generated innumerable valuable outcomes and resulted in current novel innovations; however, some challenges remain. In the case of aptamers, there are some limitations, such as a relatively short half-life, low specificity for target molecules, and exposure to serum degradation. There are also challenges with nanomaterials, including the short half-life of particles in circulation, low permeability and difficulties in large-scale synthesis. Nevertheless, aptamer-nanomaterial complexes are fascinating and have promising properties; remarkable techniques have been applied to overcome the existing weaknesses. Fervent attempts to develop innovative and creative aptamer-nanomaterial conjugates will continue, and these complexes will be recognized as novel platforms in many fields, including medical diagnostics and therapeutics.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by the National Research Foundation of Korea (NRF-2015027587) and a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Grant number: HI12C-1852-020014).

- 1 Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. *Annu Rev Med* 2005; **56**: 555–583.
- 2 Carothers JM, Oestreich SC, Szostak JW. Aptamers selected for higher-affinity binding are not more specific for the target ligand. *J Am Chem Soc* 2006; **128**: 7929–7937.
- 3 Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. *Clin Chem* 1999; **45**: 1628–1650.

- 4 Proske D, Blank M, Buhmann R, Resch A. Aptamers—basic research, drug development, and clinical applications. *Appl Microbiol Biotechnol* 2005; **69**: 367–374.
- 5 Banerjee S, Wong SS. Synthesis and characterization of carbon nanotube-nanocrystal heterostructures. *Nano Lett* 2002; **2**: 195–200.
- 6 Pavlov V, Xiao Y, Shlyahovsky B, Willner I. Aptamer-functionalized Au nanoparticles for the amplified optical detection of thrombin. *J Am Chem Soc* 2004; **126**: 11768–11769.
- 7 Lu AH, Salabas EL, Schuth F. Magnetic nanoparticles: synthesis, protection, functionalization, and application. *Angew Chem Int Ed Engl* 2007; **46**: 1222–1244.
- 8 Wang H, Yang R, Yang L, Tan W. Nucleic acid conjugated nanomaterials for enhanced molecular recognition. *ACS Nano* 2009; **3**: 2451–2460.
- 9 Yang L, Zhang XB, Ye M, Jiang JH, Yang RH, Fu T *et al*. Aptamer-conjugated nanomaterials and their applications. *Adv Drug Deliv Rev* 2011; **63**: 1361–1370.
- 10 Liu QL, Jin C, Wang YY, Fang XH, Zhang XB, Chen Z *et al*. Aptamer-conjugated nanomaterials for specific cancer cell recognition and targeted cancer therapy. *NPG Asia Mater* 2014; **6**: e95.
- 11 Ellington AD, Szostak JW. *In vitro* selection of RNA molecules that bind specific ligands. *Nature* 1990; **346**: 818–822.
- 12 Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science* 1990; **249**: 505–510.
- 13 Levesque D, Beaudoin JD, Roy S, Perreault JP. *In vitro* selection and characterization of RNA aptamers binding thyroxine hormone. *Biochem J* 2007; **403**: 129–138.
- 14 Niazi JH, Lee SJ, Gu MB. Single-stranded DNA aptamers specific for antibiotics tetracyclines. *Bioorg Med Chem* 2008; **16**: 7245–7253.
- 15 Mendonsa SD, Bowser MT. *In vitro* selection of aptamers with affinity for neuropeptide Y using capillary electrophoresis. *J Am Chem Soc* 2005; **127**: 9382–9383.
- 16 Huang CJ, Lin HI, Shiesh SC, Lee GB. Integrated microfluidic system for rapid screening of CRP aptamers utilizing systematic evolution of ligands by exponential enrichment (SELEX). *Biosens Bioelectron* 2010; **25**: 1761–1766.
- 17 Sefah K, Shangguan D, Xiong XL, O'Donoghue MB, Tan WH. Development of DNA aptamers using Cell-SELEX. *Nat Protoc* 2010; **5**: 1169–1185.
- 18 Darmostuk M, Rimpelova S, Gbelcova H, Rumi T. Current approaches in SELEX: an update to aptamer selection technology. *Biotechnol Adv* 2015; **33**: 1141–1161.
- 19 Das R, Karanicolas J, Baker D. Atomic accuracy in predicting and designing noncanonical RNA structure. *Nat Methods* 2010; **7**: 291–294.
- 20 Sarver M, Zirbel CL, Stombaugh J, Mokdad A, Leontis NB. FR3D: finding local and composite recurrent structural motifs in RNA 3D structures. *J Math Biol* 2008; **56**: 215–252.
- 21 Jiang P, Meyer S, Hou Z, Propson NE, Soh HT, Thomson JA *et al*. MPBind: a Meta-motif-based statistical framework and pipeline to Predict Binding potential of SELEX-derived aptamers. *Bioinformatics* 2014; **30**: 2665–2667.
- 22 Chushak Y, Stone MO. *In silico* selection of RNA aptamers. *Nucleic Acids Res* 2009; **37**: e87.
- 23 Slattery M, Riley T, Liu P, Abe N, Gomez-Alcala P, Dror I *et al*. Cofactor binding evokes latent differences in DNA binding specificity between Hox proteins. *Cell* 2011; **147**: 1270–1282.
- 24 Dittmar KA, Jiang P, Park JW, Amirikian K, Wan J, Shen S *et al*. Genome-wide determination of a broad ESRP-regulated posttranscriptional network by high-throughput sequencing. *Mol Cell Biol* 2012; **32**: 1468–1482.
- 25 Chen X, Zhang Q, Qian C, Hao N, Xu L, Yao C. Electrochemical aptasensor for mucin 1 based on dual signal amplification of poly(o-phenylenediamine) carrier and functionalized carbon nanotubes tracing tag. *Biosens Bioelectron* 2015; **64**: 485–492.
- 26 Jo H, Gu H, Jeon W, Youn H, Her J, Kim SK *et al*. Electrochemical aptasensor of cardiac troponin I for the early diagnosis of acute myocardial infarction. *Anal Chem* 2015; **87**: 9869–9875.
- 27 Jeon W, Lee S, Manjunatha DH, Ban C. A colorimetric aptasensor for the diagnosis of malaria based on cationic polymers and gold nanoparticles. *Anal Biochem* 2013; **439**: 11–16.
- 28 Roncancio D, Yu H, Xu X, Wu S, Liu R, Debord J *et al*. A label-free aptamer-fluorophore assembly for rapid and specific detection of cocaine in biofluids. *Anal Chem* 2014; **86**: 11100–11106.
- 29 Cella LN, Sanchez P, Zhong W, Myung NV, Chen W, Mulchandani A. Nano aptasensor for protective antigen toxin of anthrax. *Anal Chem* 2010; **82**: 2042–2047.
- 30 Hwang KS, Lee SM, Eom K, Lee JH, Lee YS, Park JH *et al*. Nanomechanical microcantilever operated in vibration modes with use of RNA aptamer as receptor molecules for label-free detection of HCV helicase. *Biosens Bioelectron* 2007; **23**: 459–465.
- 31 Bini A, Minunni M, Tombelli S, Centi S, Mascini M. Analytical performances of aptamer-based sensing for thrombin detection. *Anal Chem* 2007; **79**: 3016–3019.
- 32 Hianik T, Ostatna V, Zajacova Z, Stoikova E, Evtugyn G. Detection of aptamer-protein interactions using QCM and electrochemical indicator methods. *Bioorg Med Chem Lett* 2005; **15**: 291–295.
- 33 Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN *et al*. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. *Circulation* 2007; **116**: 2678–2686.
- 34 Sayyed SG, Hagele H, Kulkarni OP, Endlich K, Segerer S, Eulberg D *et al*. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. *Diabetologia* 2009; **52**: 2445–2454.
- 35 Min K, Jo H, Song K, Cho M, Chun YS, Jon S *et al*. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (–) prostate cancers. *Biomaterials* 2011; **32**: 2124–2132.
- 36 Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR *et al*. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. *Nat Biotechnol* 2009; **27**: 839–849.
- 37 Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R *et al*. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. *Nano Lett* 2007; **7**: 3065–3070.
- 38 Zhou D. Quantum dot-nucleic acid/aptamer bioconjugate-based fluorimetric biosensors. *Biochem Soc Trans* 2012; **40**: 635–639.
- 39 Zhang CY, Johnson LW. Single quantum-dot-based aptameric nanosensor for cocaine. *Anal Chem* 2009; **81**: 3051–3055.
- 40 Liang H, Zhang XB, Lv Y, Gong L, Wang R, Zhu X *et al*. Functional DNA-containing nanomaterials: cellular applications in biosensing, imaging, and targeted therapy. *Acc Chem Res* 2014; **47**: 1891–1901.
- 41 Medley CD, Smith JE, Tang Z, Wu Y, Bamrungsap S, Tan W. Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells. *Anal Chem* 2008; **80**: 1067–1072.
- 42 Song KM, Jeong E, Jeon W, Cho M, Ban C. Aptasensor for ampicillin using gold nanoparticle based dual fluorescence-colorimetric methods. *Anal Bioanal Chem* 2012; **402**: 2153–2161.
- 43 He XX, Wang K, Tan W, Liu B, Lin X, He C *et al*. Bioconjugated nanoparticles for DNA protection from cleavage. *J Am Chem Soc* 2003; **125**: 7168–7169.
- 44 Cai L, Chen ZZ, Chen MY, Tang HW, Pang DW. MUC-1 aptamer-conjugated dye-doped silica nanoparticles for MCF-7 cells detection. *Biomaterials* 2013; **34**: 371–381.
- 45 Jo H, Her J, Ban C. Dual aptamer-functionalized silica nanoparticles for the highly sensitive detection of breast cancer. *Biosens Bioelectron* 2015; **71**: 129–136.
- 46 Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chioocca EA *et al*. *In vivo* magnetic resonance imaging of transgene expression. *Nat Med* 2000; **6**: 351–355.
- 47 Bamrungsap S, Shukoor MI, Chen T, Sefah K, Tan W. Detection of lysozyme magnetic relaxation switches based on aptamer-functionalized superparamagnetic nanoparticles. *Anal Chem* 2011; **83**: 7795–7799.
- 48 Hesketh PJ. Chemotherapy-induced nausea and vomiting. *N Engl J Med* 2008; **358**: 2482–2494.
- 49 Jelveh S, Chithrani DB. Gold nanostructures as a platform for combinational therapy in future cancer therapeutics. *Cancers* 2011; **3**: 1081–1110.
- 50 Wang J, Zhu G, You M, Song E, Shukoor MI, Zhang K *et al*. Assembly of aptamer switch probes and photosensitizer on gold nanorods for targeted photothermal and photodynamic cancer therapy. *ACS Nano* 2012; **6**: 5070–5077.
- 51 Jo H, Youn H, Lee S, Ban C. Ultra-effective photothermal therapy for prostate cancer cells using dual aptamer-modified gold nanostars. *J Mater Chem B* 2014; **2**: 4862–4867.
- 52 Luo YL, Shiao YS, Huang YF. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy. *ACS Nano* 2011; **5**: 7796–7804.

- 53 Zhou J, Rossi JJ. Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. *Mol Ther Nucleic Acids* 2014; **3**: e169.
- 54 Kang H, O'Donoghue MB, Liu H, Tan W. A liposome-based nanostructure for aptamer directed delivery. *Chem Commun* 2010; **46**: 249–251.
- 55 Mu CF, Dave N, Hu J, Desai P, Pauletti G, Bai SH *et al*. Solubilization of flurbiprofen into aptamer-modified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells *in vitro*. *J Microencapsul* 2013; **30**: 701–708.
- 56 Lee H, Yu MK, Park S, Moon S, Min JJ, Jeong YY *et al*. Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer *in vivo*. *J Am Chem Soc* 2007; **129**: 12739–12745.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>